OrthoPediatrics (NASDAQ:KIDS) Stock Price Expected to Rise, BTIG Research Analyst Says

OrthoPediatrics (NASDAQ:KIDS) had its price target hoisted by research analysts at BTIG Research from $23.00 to $24.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 25.20% from the stock’s current price.

KIDS has been the subject of several other reports. Canaccord Genuity Group initiated coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. Needham & Company LLC lifted their price target on OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen lowered OrthoPediatrics from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, TD Cowen raised OrthoPediatrics to a “strong-buy” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and an average price target of $24.44.

OrthoPediatrics Trading Up 7.8%

KIDS stock opened at $19.17 on Friday. OrthoPediatrics has a one year low of $15.28 and a one year high of $26.40. The stock has a market cap of $480.78 million, a price-to-earnings ratio of -11.34 and a beta of 1.12. The company has a fifty day moving average price of $17.64 and a two-hundred day moving average price of $18.14. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. The company had revenue of $61.61 million during the quarter, compared to analysts’ expectations of $61.27 million. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.68%. Equities analysts anticipate that OrthoPediatrics will post -0.93 EPS for the current year.

Institutional Trading of OrthoPediatrics

Several large investors have recently made changes to their positions in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after acquiring an additional 645 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of OrthoPediatrics by 12.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock worth $342,000 after buying an additional 1,753 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Q4 beat — OrthoPediatrics reported EPS of ($0.26) vs. consensus ($0.37) and revenue of $61.61M vs. $61.27M, a combination that surprised the market to the upside. Earnings Release
• Positive Sentiment: Needham raised its price target to $30 and reiterated a Buy — the new target implies material upside versus the current share level and likely supported buying interest. Benzinga
• Positive Sentiment: BTIG also raised its target to $24 and kept a Buy rating, adding further analyst support to the stock move. Benzinga
• Positive Sentiment: Company reiterated 2026 revenue guidance of $262M–$266M and described an accelerating “product innovation super‑cycle,” which management frames as a multi‑year growth driver. Seeking Alpha
• Neutral Sentiment: Investor access: OrthoPediatrics announced participation in upcoming investor conferences, which should help management communicate the growth story but is not material on its own. GlobeNewswire
• Neutral Sentiment: Analyst/media coverage and detailed call notes/transcript are circulating (earnings transcript and coverage from Yahoo, Zacks, Seeking Alpha), which helps investors parse the quarter. Yahoo Finance
• Negative Sentiment: Profitability remains a concern — OrthoPediatrics is still loss‑making (negative net margin ~20% and negative ROE), and consensus expects negative full‑year EPS, which limits valuation multiple expansion until sustained profit improvement. Zacks

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.